Saboya-Galindo P, Mejia-Salgado G, Cifuentes-Gonzalez C, Rodriguez-Rodriguez C, Boada-Robayo L, Mendez-Marulanda R
PLoS One. 2024; 19(10):e0307455.
PMID: 39453915
PMC: 11508149.
DOI: 10.1371/journal.pone.0307455.
Stubiger N, Ruprecht K, Pleyer U
Ophthalmologie. 2024; 121(8):665-678.
PMID: 39037464
DOI: 10.1007/s00347-024-02084-8.
McIlwaine G, Csincsik L, Coey R, Wang L, Fitzgerald D, Moffat J
Ophthalmol Sci. 2023; 3(3):100308.
PMID: 37214765
PMC: 10199246.
DOI: 10.1016/j.xops.2023.100308.
Helal R, Arya S, Abu Sbeit R, Elshafei M
J Ophthalmic Inflamm Infect. 2023; 13(1):13.
PMID: 36947273
PMC: 10032265.
DOI: 10.1186/s12348-023-00337-2.
Shah R, Mahale R, Babu K, Shah D, Vincent M, Nanda S
Ann Indian Acad Neurol. 2022; 25(2):296-298.
PMID: 35693643
PMC: 9175400.
DOI: 10.4103/aian.aian_356_21.
Incidence of uveitis and macular edema among patients taking fingolimod 0.5 mg for multiple sclerosis.
Sonne S, Smith B
J Ophthalmic Inflamm Infect. 2020; 10(1):24.
PMID: 32954456
PMC: 7502642.
DOI: 10.1186/s12348-020-00215-1.
Uveitis, optic neuritis and MOG.
Gupta P, Goyal V, Srivastava A, Pandit A, Prasad K
Mult Scler J Exp Transl Clin. 2020; 6(2):2055217320925107.
PMID: 32489673
PMC: 7238848.
DOI: 10.1177/2055217320925107.
Objective quantification of vitreous haze on optical coherence tomography scans: no evidence for relationship between uveitis and inflammation in multiple sclerosis.
Coric D, Ometto G, Montesano G, Keane P, Balk L, Uitdehaag B
Eur J Neurol. 2019; 27(1):144-e3.
PMID: 31342606
PMC: 6916624.
DOI: 10.1111/ene.14048.
Acute hypertensive uveitis as the first presentation of multiple sclerosis.
Shields M, Simon S, Chan W, Gilhotra J
Indian J Ophthalmol. 2018; 67(1):163-164.
PMID: 30574934
PMC: 6324108.
DOI: 10.4103/ijo.IJO_345_18.
[Intraocular inflammation in multiple sclerosis].
Stubiger N, Ruprecht K, Pleyer U
Ophthalmologe. 2018; 115(6):531-542.
PMID: 29536169
DOI: 10.1007/s00347-018-0673-5.
Characteristics of morphologic macular abnormalities in neuroimmunology practice.
Al-Louzi O, Sotirchos E, Vidal-Jordana A, Beh S, Button J, Ying H
Mult Scler. 2017; 25(3):361-371.
PMID: 29125422
PMC: 6929206.
DOI: 10.1177/1352458517741206.
Intermediate uveitis: pattern of etiology, complications, treatment and outcome in a tertiary academic center.
Ness T, Boehringer D, Heinzelmann S
Orphanet J Rare Dis. 2017; 12(1):81.
PMID: 28449695
PMC: 5408401.
DOI: 10.1186/s13023-017-0638-9.
Multiple Sclerosis and Panuveitis: A Rare Association.
Cokal B, Gunes H, Guler S, Yoldas T, Baydar C, Kavuncu S
Noro Psikiyatr Ars. 2017; 53(1):94-95.
PMID: 28360778
PMC: 5353250.
DOI: 10.5152/npa.2015.8790.
The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.
Heath G, Airody A, Gale R
Drugs. 2017; 77(3):303-311.
PMID: 28181178
DOI: 10.1007/s40265-017-0692-6.
Unusual presentation of a multiple sclerosis case involving central retinal artery occlusion.
Galvez-Ruiz A, Nowilaty S
Saudi J Ophthalmol. 2015; 29(2):160-4.
PMID: 25892937
PMC: 4398801.
DOI: 10.1016/j.sjopt.2014.12.001.
Uveitis associated with multiple sclerosis: complications and visual prognosis.
Kaya D, Kaya M, Ozakbas S, Idiman E
Int J Ophthalmol. 2014; 7(6):1010-3.
PMID: 25540756
PMC: 4270967.
DOI: 10.3980/j.issn.2222-3959.2014.06.18.
Vision and vision-related outcome measures in multiple sclerosis.
Balcer L, Miller D, Reingold S, Cohen J
Brain. 2014; 138(Pt 1):11-27.
PMID: 25433914
PMC: 4285195.
DOI: 10.1093/brain/awu335.
[Uveitis in multiple sclerosis : Overview and perspectives].
Hildebrandt A, Mackensen F
Ophthalmologe. 2014; 111(8):733-9.
PMID: 25092024
DOI: 10.1007/s00347-013-2984-x.
Gender disparities in ocular inflammatory disorders.
Sen H, Davis J, Ucar D, Fox A, Chao Chan C, Goldstein D
Curr Eye Res. 2014; 40(2):146-61.
PMID: 24987987
PMC: 4282612.
DOI: 10.3109/02713683.2014.932388.
Gender and uveitis in patients with multiple sclerosis.
Gordon L, Goldstein D
J Ophthalmol. 2014; 2014:565262.
PMID: 24891944
PMC: 4033526.
DOI: 10.1155/2014/565262.